Rybak V.A., Maloshtan L.N.
The usage of thick bean extract, metformin and glibenclamide for correction of dithizone diabetes complications in rabbits
National University of Pharmacy, Ukraine
Abstract.
We have studied the influence of the thick bean extract (TBE), metformin and glibenclamide on the level of glucose and ketone bodies in the urine, urine pH on the model of dithizone diabetes in rabbits. In 7, 10, 12 and 14 days of the research the TBE reduced glucose level in the urine of animals and prevailed over the effect of metformin by 9,8%, 9,7%, 31,2% and 37,4%, but was inferior to the action of glibenclamide by 4,5%, 5,9 %, 1,3% and 0,7%. The TBE reduced the level of ketone bodies in the urine of the animals in 7, 10, 12 and 14 days of the study, and prevailed over the effect of metformin by 5,5%, 10,2%, 8,4% and 12,0%, but was inferior to the action of glibenclamide in 7, 10 and 14 days of the study by 4,1%, 3,8% and 3,3%, and in 12 days – the TBE predominated over the effect of glibenclamide by 2,4%. On the 14th day of the research the TBE facilitated the normalization of urine pH in the animals, which corresponded (8,4±0,38) to alkaline medium. In the group of animals for the treatment of which glibenclamide was applied, urine pH approximated to the original data (7,9±0,40), but urine pH was still acidic (7,5±0,51) when metformin was used in the treatment of animals. It was found out that the long-term administration of the TBE, beginning with the 7th day and during 14 days of the study decreased blood glucose and ketone bodies levels in the urine, helped to normalize urine pH in the animals with dithizone diabetes, prevailed over the action of metformin and approximated to the action of glibenclamide. Thus the TBE is a promising hypoglycemic agent in the complex treatment of acute insulin deficiency, as well as in the treatment of DM of the 2nd type in animals, which will enable the prevention of the development of the disease complications.
Key words: dithizone diabetes, metformin, glibenclamide, thick bean extract.
References
1. Dedov II. Sakharnyi diabet [Diabetes]: rukovodstvo dlia vrachei. Moscow, RF: Universum Pablishing; 2003. 455 р.
2. KDOQI Clinical Practice Guidelines and Clinical Practice recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis.2007 Feb;49(2 Suppl 2):S12-154.
3. Noto H, Goto A, Tsujimoto T, Noda M. Caner risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7(3):e33411.
4. Balabolkin MI, Klebanova EM, Kreminskaya VM. Lechenie sakharnogo diabeta i ego oslozhnenii [Treatment of diabetes and its complications]: ucheb. posobie. Moscow, RF: Meditsina; 2005. 512 р.
5. Marshall SM, Walker M, Alberti KGM. Diabetic ketoacidosis and hyperglycemic non-ketotic coma. In: Alberti KGM, Zimmet P, DeFronzo RA, editors. International textbook of diabetes mellitus. New York: John Wiley; 1997. p. 1215-29.
6. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52.
7. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in tyre 2 diabetes. Diabetologia. 2009 Sep;52(9):1766-77.
8. Evans TC, Capell P. Diabetic nephropathy. Clinical Diabetes. 2000;18(1):1-16.
9. Shuliarenko LV. Khronіchna dіabetichna khvoroba nirok: suchasnii pogliad na problemu [Chronic diabetic kidney disease: a modern approach to the problem]. Endokrinologіia. 2013;18(1):73-82.
10. Chernikh VP, Maloshtan LM, Gorbenko NІ, Voronіna LM, Kovaliov VM, Merzlіkіn SІ. Suchasnі aspekti peroral'noї farmakoterapії tsukrovogo dіabetu 2 tipu. Dosiagnennia NfaU [Modern aspects of oral pharmacotherapy for type 2 diabetes. Achievements pharmacy]: monografіia. Kharkіv, Ukraina: BURUN і K; 2010. 208 р.
11. Stefanov AV, red. Doklinicheskie issledovaniia lekarstvennykh sredstv [Preclinical researches of medicines]: metod. rek. Kiev, Ukraina: Avitsenna; 2001. 528 р.
12. Zapadniuk IP, Zapadniuk VI, Zakhariia EA, Zapadniuk BV. Laboratornye zhivotnye. Razvedenie, soderzhanie, ispol'zovanie v eksperimente [Laboratory animals. Breeding, maintenance, use in the experiment]. Kiev, Ukraina: Vishcha shkola; 1983. 383 р.
13. Rybolovlev YuR. Dozirovanie veshchestv dlia mlekopitaiushchikh po konstante biologicheskoi aktivnosti [Dosing agents for mammalian constant biological activity]. Doklady AN SSSR. 1979;247(6):1513-6.
14. Rybak VA, Maloshtan LN. Izuchenie gipoglikemicheskoi aktivnosti gustogo ekstrakta fasoli na modeli ditizonovogo diabeta [Studying of hypoglycemic activity of dense extract of haricot on model of ditizonovy Diabetum]. Meditsina i obrazovanie v Sibiri. 2014;(3). Rezhim dostupa: http://ngmu.ru/cozo/mos/article/text_full.php&id=1441.
15. Mankowski BM, Larіn OS. Vchasna dіagnostika tsukrovogo dіabetu: rezul'tati doslіdzhennia Dіa Skrin 50 [Timely diagnosis of diabetes mellitus: results of the Dia Screen 50]. Klіnіchna endokrinologіia ta endokrinologіchna khіrurgіia. 2007;(1):42-8.
16. Kamyshnikov VS. Spravochnik po kliniko-biokhimicheskim issledovaniiam i laboratornoi diagnostike [Handbook of clinical and biochemical studies and laboratory diagnosis]. Moscow, RF: MEDpress-inform; 2009. 896 р.
